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Abstract
Background: Overexpression of Bmi-1 has been observed in a variety of cancers, and it has been suggested to be
an independent prognostic marker for the patients. The objective of this study was to determine the level of Bmi-1
expression or its autoantibodies in human esophageal squamous cell carcinoma (ESCC) and to correlate it with
clinicopathologic data.
Methods: We first examined Bmi-1 expression in ESCC cell lines and tumor samples by RT-PCR and Western blot
analysis. We then analyzed Bmi-1 protein expression in 171 clinicopathologically characterized ESCC cases by
immunohistochemistry. In addition, we detected its autoantibodies in sera of patients with ESCC by ELISA.
Results: We found that Bmi-1 expression was higher in the immortalized cells, cancer cell lines and most cancer
tissue than in non-tumorous control tissue at both mRNA and protein level. In addition, Bmi-1 expression was
observed in 64.3% (110 of 171) archive ESCC specimen by immunohistochemistry analysis, and the location of Bmi-
1 in ESCC was in the nuclei instead of cytoplasm of tumor cells. There was a significant difference of Bmi-1
expression in patients categorized according to stage (P = 0.003) and pN classification (P = 0.047). Multivariate
analysis suggested that Bmi-1 expression was an independent prognostic marker for ESCC patients. A prognostic
significance of Bmi-1 was also found in the subgroup of T3~T4 and N1 tumor classification. Bmi-1 autoantibodies
were detected in sera of 39.0% (62 of 159) ESCC patients. The correlations between anti-Bmi-1 antibodies and
tumor stage (P = 0.040), or lymph node status (P < 0.001) were significant.
Conclusions: Our results suggest that Bmi-1 protein is a valuable marker of ESCC progression. The presence of
Bmi-1 autoantibodies in sera from patients with ESCC may have clinical utility in esophageal cancer diagnosis.
Background
Esophageal squamous cell carcinoma (ESCC), the major
histological type of esophageal cancer, is the sixth most
frequent cause of cancer death worldwide[1], and
accounts for the fourth largest number of cancer death
in China[2]. However, the molecular mechanism of its
development and progression remains poorly under-
stood[3]. Despite considerable diagnostic and therapeu-
tic advances in the treatment of ESCC in recent years
[4], there is still an urgent need for further identification
of novel molecular markers to provide the clinician with
useful information concerning patient prognosis and
possible therapeutic options. Several factors, such as
cyclin D1[5], Ki-67[6], nm23-H1[7], Fas[8] and CENP-H
[9] have been reported previously as potentially useful
prognostic markers in ESCC.
Bmi-1 (B-cell-specific Moloney murine leukemia virus
integration site 1) was originally isolated as an oncogene
that cooperates with c-myc in the generation of mouse
pre B-cells lymphomas[10,11].I ti sat r a n s c r i p t i o n a l
repressor belonging to the Polycomb-group (PcG) family
of proteins involved in axial patterning, hematopoiesis,
regulation of proliferation, and senescence[12,13]. It has
been reported that Bmi-1 contributes to cell cycle
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any medium, provided the original work is properly cited.regulation by acting as a stable transcriptional repressor
of the INK4a/ARF locus[14]. Bmi-1 overexpression leads
to activation of human telomerase reverse transcriptase
transcription and induction of telomerase activity in
immortalized mammary epithelial cells[15]. We have
also reported that overexpression of Bmi-1 leads to the
induction of telomerase activity, reduction of p16INK4a
expression, and immortalization of normal nasophary-
geal epithelial cells (NPECs)[16]. A recent report has
shown that Bmi-1 autoantibodies were newly potential
biomarkers of nasopharyngeal cancer[17]. In addition, it
has been found that Bmi-1 is overexpressed in a variety
of human cancers, such as mantle cell lymphomas[18],
non-small cell lung cancer[19], B-cell non-Hodgkin’s
lymphoma[20], breast cancer[21], colorectal cancer[22],
prostate cancer[23], nasopharyngeal carcinoma[16] and
gastric carcinoma[24]. In these reports, Bmi-1 protein
mainly locates in nuclei of tumor cells. Recently, He et
a l . [ 2 5 ]r e p o r t e dt h a tB m i - 1w a so v e r e x p r e s s e di ne s o -
phageal squamous cell carcinomas, and Bmi-1 mRNA
expression correlated with lymph node metastases,
pathological stage and poor prognosis of the patients.
However, they found that Bmi-1 protein was largely dis-
tributed in the cytoplasm of tumour cells, and there was
no significant clinical relevance with Bmi-1 protein
expression. Thus, it is required further investigation to
determine whether the cytoplasm staining represents the
real localization of Bmi-1, and whether Bmi-1 plays a
different role in the development of ESCC.
Here, we found that overexpression of Bmi-1 was
observed in both ESCC cell lines and tumor tissue.
Moreover, the location of Bmi-1 in ESCC was in the
nuclei instead of cytoplasm of tumor cells. The expres-
sion of Bmi-1 was correlated with the stage and pN
classification of the disease. Multivariate analysis sug-
gested that Bmi-1 expression was an independent prog-
nostic marker for ESCC patients. In addition, Bmi-1
autoantibodies were presented in sera from patients
with ESCC and weren’t detected in sera from healthy
control. Our results strongly suggest that the expression
level of Bmi-1 might be used as a valuable prognostic
marker for ESCC patients and Bmi-1 autoantibodes in
serum may have potential clinical utility in ESCC
diagnosis.
Methods
Cell lines
The primary esophageal epithelial cells was generated as
described and cultured in Keratinocyte-SFM (Invitrogen,
Carlsbad, CA) [3]. The immortalized esophageal epithe-
lial cell line NE-3 induced by human papillomavirus
type 16 E6/E7 and the ESCC cell line 108CA were
obtained from Dr. Jin (the University of Hong Kong, P.
R. China) and were cultured in Keratinocyte-SFM
(Invitrogen, Carlsbad, CA) [3,9]. The ESCC cell lines
Eca-109, TE-1, and Kyse140 (Cell Bank of Type Culture
Collection of Chinese Academy of Sciences, Shanghai,
China) were grown in RPMI 1640 (Invitrogen) supple-
mented with 10% fetal bovine serum[9].
Sera
A group of 159 patients with ESCC who underwent
tumor resection at the cancer center of Sun Yet-sen uni-
versity from January 2005 to January 2007 was enrolled
in this study. This group included 96 males and 63
females, with age ranging from 42 to 87 years (mean, 63
years). Sera of the patients were obtained at the time of
diagnosis before treatment. Sera from 102 healthy
volunteers, including 75 males and 27 females with ages
from 41 to 71 years (mean, 58 years), were collected
and used as control. Prior to the use of these sera for
investigation, informed consent of patients and approval
from the Institute Research Ethics Committee were
obtained. After collection, sera were aliquoted and
stored at -80°C until use.
Tissue specimen
Eight pairs of ESCC tissue specimen and corresponding
nontumorous specimen were obtained from patients
with ESCC who underwent surgical esophageal tissue
resection at the Cancer Center of Sun Yat-sen Univer-
sity (Guangzhou, P. R. China) during 2007. Written
informed consent was obtained from each patient before
surgery. All excised samples were obtained within 1 h
after the operation from tumor tissue and corresponding
nontumorous tissue 5-10 cm away from the tumor, and
then were immediately kept in liquid nitrogen until
further analysis. In addition, immunohistochemstry ana-
lysis was conducted on 171 paraffin-embedded ESCC
samples which were histologically and clinically diag-
nosed from the Cancer Center, Sun Yat-sen University,
between 2001 and 2004. None of them had received
radiation therapy or chemotherapy before surgery. Prior
to the use of these clinical materials for investigation,
informed consent from patients and approval from the
Institute Research Ethics Committee were obtained).
Primary cancers of the esophagus were classified accord-
ing to the pathological TNM classification[26]. Clinical
information of 171 ESCC samples was described in
detail as shown in Table 1. Patients included 129 males
and 42 females, of ages ranging from 33 to 82 years
(mean, 56.7 years). The figures on metastasis pertain to
its presence at any time in follow-up. The median fol-
low-up period for overall survival was 25.0 months for
patients still alive at the time of analysis, and it was ran-
ged from 1 to 78 months. A total of 112 (65.5%)
patients died during follow-up period. Prior to the use
of all of the clinical materials for investigation, informed
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Research Ethics Committee were obtained.
RNA extraction, reverse transcription (RT) and real-time
PCR
Total RNAs from cells and primary tumor tissue were
extracted using the Trizol reagent (Invitrogen) according
to the manufacturer’s instruction. The RNAs were pre-
treated with RNAase-free DNase and 2 μg RNA from each
sample was used for cDNA synthesis with random hexam-
ers. Real-time PCR was then employed to determine the
fold change of Bmi-1 mRNA both in the primary esopha-
geal tumor and in its paired normal esophageal tissue
taken from the same patient. Expression data were nor-
malized to the geometric mean by housekeeping gene Gly-
ceraldehyde-3-phosphate dehydrogenase (GAPDH), which
was used as an internal control. RT-PCR primers for Bmi-
1 and GAPDH cDNA were as follows, Bmi-1 sense,
5′-ATGCATCGAACAACGAGAATCAAGATCACT-3′;
Bmi-1 antisense, 5′-TCAACCAGAAGAAGTTGCTGATG
ACCC-3′; GAPDH sense, 5′-AATCCCATCACCATC
TTCCA-3′; GAPDH antisense, 5′-CCTGCTTCACCAC
CTTCTTG-3′. The sequences of the primers and probe
for real-time PCR of Bmi-1 and GAPDH were listed as fol-
lows, Bmi-1 sense: 5′-CTGGTTGCCCATTGACAGC-3′;
Bmi-1 antisense: 5′-CAGAAAATGAATGCGAGCCA-3′;
GAPDH sense: 5′-GACTCATGACCACAGTCCATGC-3′;
GAPDH antisense: 5′-AGAGGCAGGGATGATGTTCTG-
3′.T h ep r o b e sf o rBmi-1,5 ′- CAGCTCGCTTCAA-
GATGGCCGC-3′,a n df o rGAPDH,5 ′-CATCACTG
CCACCCAGAAGACTGTG-3′, were labeled with 6-car-
boxy-fluorescein as the reporter dye.
Western blot analysis
Western blot analysis of Bmi-1 expression was per-
formed as described previously[16]. Bmi-1 was detected
using a mouse monoclonal antibody against Bmi-1
(Upstate Biotechnology, Lake Placid, USA). An anti-a-
tubulin mouse monoclonal antibody (1:1,000; Santa
Cruz Biotechnology, Santa Cruz, CA) was used to con-
firm equal loading. Sera Bmi-1 autoantibodies were con-
firmed by Western blot analysis. Briefly, the
recombinant Bmi-1 protein was separated by SDS-
PAGE (1 μg/lane) and then blotted on PVDF. The
membrane was cut into strips and incubated with 1 ml
of serum samples diluted 1:100 in 3% skim dry milk
solution in TBS. Strips were then incubated for 1 h with
1 ml of 1:2500 diluted goat F (ab’)2 antihuman IgG
labeled with horseradish peroxidase (Coulter Immuno-
diagnostics) in TBST and enhanced chemiluminescence.
Immunohistochemistry
Immunohistochemistry was done to study altered pro-
tein expression in 171 human ESCC tissue,which was
the same samples as our previous report[9]. The proce-
dure was described previously[16]. Briefly, mouse mono-
clonal anti-Bmi-1 (1:150, Upstate Biotechnology, Lake
Placid, USA) was incubated with the sections overnight
at 4°C. For negative controls, the primary antibody was
replaced by normal mouse serum. After washing, the tis-
sue sections were treated with biotinylated anti-mouse
secondary antibody (Zymed, San Francisco, CA), fol-
lowed by further incubation with streptavidin HRP com-
plex (Zymed). The degree of immunostaining of
formalin-fixed, paraffin-embedded sections was reviewed
and scored by two independent observers. The propor-
tion of the stained cells and the extent of the staining
were used as criteria of evaluation. For each case, at
least 1,000 tumor cells were analyzed and the percentage
of positively nuclear stained tumor cells was recorded.
For each sample, the proportion of Bmi-1-expressing
cells varied from 0% to 100%, and the intensity of
nuclear staining varied from weak to strong. One score
was given according to the percent of positive cells as:
Table 1 Correlation between the clinicopathologic
features and expression of Bmi-1 protein
Characteristics Bmi-1 expression P
No or low High
Age(y) 55.8 ± 10.4 57.6 ± 9.9 0.576
Gender
Male 61(47.3) 68(52.7) 0.970
Female 20(47.6) 22(52.4)
Stage
I-IIa 50(58.8) 35(41.2) 0.003
IIb-IV 31 (36.0) 55(64.0)
Histological differentiation
Well 31(56.4) 24(43.6)
Moderate 29(40.3) 43(59.7) 0.315
Poor 21(47.7) 23(52.3)
Tumor diameter
<40 mm 29(40.3) 43(59.7) 0.115
≥40 mm 52(52.5) 47(47.5)
Depth of invasion
Submucosa 6(50.0) 6(50.0) 0.782
Muscularis propria 28(48.3) 30(51.7)
Adventitia 47(46.5) 54(53.5)
pT classification
T1 ~ T2 32(54.2) 27(45.8) 0.194
T3 ~ T4 49(43.8) 63(56.3)
pN classification
YES 30(39.0) 47(61.0) 0.047
NO 51(54.3) 43(45.7)
pMetastasis
YES 5(55.6) 4 (44.4) 0.616
NO 76(46.9) 86 (53.1)
* The percentages in Table 1 are the row percentages.
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70% of the cells: 3 point; ≥71% of the cells: 4 point.
Another score was given according to the intensity of
staining as negative staining: 1 point; weak staining
(light yellow): 2 point; moderate staining (yellowish
brown): 3 point; and strong staining (brown): 4 point. A
final score was then calculated by multiple the above
two scores. If the final score was equal or bigger than
four, the tumor was considered high expression; other-
wise, the tumor was considered low expression [9,27].
Preparation of Recombinant Bmi-1 protein
GST-Bmi-1 construct was generated by subcloning the
PCR-amplified human Bmi-1 coding sequence into
pGEX-4T1. Overexpression in Escherichia coli and puri-
fication were performed according to the manufacturer’s
protocol (Amersham Pharmacia Biotech). The purified
Bmi-1 protein was obtained by elution after cleavage.
Purity of the recombinant protein was determined by
SDS-PAGE and Coomassie Blue staining.
ELISA
Purified recombinant Bmi-1 was diluted in 50 mM
bicarbonate buffer (pH 9.5) to a final protein concentra-
tion of 5 mg/ml as determined by the Bradford assay
(Bio-Rad Laboratories). The Bmi-1 solutions were dis-
pensed into 96-well plates (100 μl/well) and incubated
overnight at 4°C. The diluted serum samples (1:100 in
PBST) were added at 100 μl per precoated well. Each
well was determined with 100 μl of a 1:5,000 dilution of
goat antihuman IgG-HRP conjugate (Santa Cruz). After
a final PBST washing, TMB developing reagent was
added for 15 min. Reaction was then stopped with 0.5
MH 2SO4 and read at OD of 450 nm. All serum samples
were run in duplicate and randomly distributed on the
plates. Sera from cancer patients and sera from healthy
volunteers were tested simultaneously.
Statistical analysis
All statistical analyses were carried out using the SPSS
13.0 statistical software package. Mann-Whitney U test
was used to analyze the relationship between Bmi-1
expression and clinicopathologic characteristics in
archival esophageal cancer tissue and look for an asso-
ciation between Bmi-1 autoantibodies and clinico-
pathologic variables in blood samples from ESCC
cancer patients. Pearson’s chi-squared test was used to
analyze the relationship between Bmi-1 expression and
gender. Survival curves were plotted by the Kaplan-
Meier method and compared by the log-rank test. The
significance of various variables for survival was ana-
lyzed by the Cox proportional hazards model in the
multivariate analysis. P < 0.05 in all cases was consid-
ered statistically significant.
Results
Expression of Bmi-1 in esophageal carcinoma cell lines
Western blotting analysis showed that Bmi-1 protein
was highly expressed in four esophageal cancer cell lines
(108CA, Kyse 140, Eca-109 and TE-1) and HPV E6/E7
induced immortalized cell line NE-3, whereas it was
weakly detected in normal esophageal tissue (Fig. 1A).
The overexpression of Bmi-1 protein in ESCC cell lines
(108CA, Kyse 140, Eca-109) was further confirmed
when compared to that in the primary cultured esopha-
geal epithelial cells from two independent donors (Addi-
tional file 1: Fig.S1). To determine whether the Bmi-1
upregulation was also at the mRNA level, RT-PCR and
real-time PCR were performed. As shown in Fig. 1B and
Figure 1 Overexpression of Bmi-1 in immortalized esophageal
epithelial cell line and esophageal carcinoma cell lines.
Expression of Bmi-1 protein (A), mRNA (B and C) in immortalized
esophageal epithelial cell line (NE-3) and esophageal carcinoma cell
lines (108CA, Kyse 140, Eca-109 and TE-1) analyzed by Western blot
(A), RT-PCR (B) or real-time PCR (C). N was a normal esophageal
tissue. Expression level was normalized by a-Tubulin or GAPDH.
Error bars represent standard deviations (SD) calculated from three
parallel experiments.
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cancer cell lines and the immortalized NE-3 cells unex-
ceptionally showed high level expression of Bmi-1
mRNA, while the normal esophageal tissue expressed a
relatively low level of Bmi-1 mRNA.
Expression of Bmi-1 in paired esophageal tumor and
nontumorous tissue
We next determined whether Bmi-1 is overexpressed in
esophageal carcinoma samples. As shown in Fig. 2A, the
expression level of Bmi-1 protein in cancer tissue was
higher than that in the paired non-tumor tissues. Con-
sistent with the upregulated protein level, Bmi-1 mRNA
expression was also upregulated in tumor tissue com-
pared with the paired non-tumor tissue as analyzed by
real-time PCR (Fig. 2B). The tumor/normal (T/N) ratio
of Bmi-1 message signals varied from approximately 2.5-
to 20-fold in eight paired tissue. Thus, Bmi-1 is overex-
pressed at both mRNA and protein levels in the most of
eight pairs of ESCC tumors examined.
Expression of Bmi-1 in archival esophageal cancer tissue
We further analyzed the expression and subcellular
localization of Bmi-1 protein by immunohistochemistry.
Bmi-1 protein was detected in 110 of 171 ESCC samples
(64.3%). Bmi-1 protein was mainly located in nuclei of
tumor cells (Fig.3C and 3D). Higher expression of Bmi-
1 was observed in invasive front of esophageal carci-
noma tissue (Fig.3E and 3F). However, only weak Bmi-1
staining was observed in some basal cells of adjacent
normal esophageal epithelium (Fig. 3A and 3B) and in
few surrounding stroma cells.
Figure 2 Overexpression of Bmi-1 in ESCC tumors. Eight paired primary esophageal tumors (T) and normal esophageal tissue (N) from the
same patient were determined for Bmi-1 expression at protein level by Western blot (A), or at mRNA level by real-time PCR (B). Expression level
was normalized by a-Tubulin or GAPDH. Error bars represent standard deviations (SD) calculated from three parallel experiments.
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the 8 paired fresh tissues were not consistent with the
results of immunostaining in the archive tissue samples.
To clarify the discrepancy, immunohistochemical analy-
sis of the 8 paired tissues was carried out. The represen-
tative results were shown in Additional File 2: Fig.S2.
Case 4 and case 8 contained high amounts of tumor
cells with high levels of Bmi-1 expression. Case 1, case 2
and case 3 showed relatively low amounts of tumor cells
with high levels of Bmi-1 expression, whereas case 5,
case 6 and case 7 showed low level of Bmi-1 expression
in tumor cells
Correlation between Bmi-1 protein expression and
clinicopathological features
Table 1 shows the relationship between the expres-
sion of Bmi-1 protein and clinical characteristics in
171 ESCC cases. There was no significant correlation
between the expression level of Bmi-1 protein and
age, histological classification, histological differentia-
tion, tumor diameter, depth of invasion, T classifica-
tion or distant metastasis of esophageal cancer
patients. Due to the number of cases with stage I, IIb
and IV is small and a relatively high frequent expres-
sion in patients with IIb in comparison to IIa and I,
we combined patients into two groups according the
stage, one group with stage I and IIa, and the other
group with stage IIb, III and IV. There is significant
difference of Bmi-1expression between the early
stages (I plus IIa) and other stages (IIb-IV) (P =
0.003). In addition, the expression of Bmi-1 is closely
associated with pN classification (P = 0.047). The
expression of Bmi-1 protein was positively correlated
with staging and pN classification (Table 1). Higher
staging and N classification correlated with higher
Bmi-1 expression.
Figure 3 Expression of Bmi-1 protein in tissue by immunohistochemistry. A and B, only weak staining of Bmi-1 was detected in few
normal esophageal epithelial tissue (arrow, normal epithelial cells). C and D, positive expression of Bmi-1 in esophageal carcinoma tissues (200×
and 400× of magnification, respectively). E and F, representative case of higher expression of Bmi-1 in invasive front (arrow, 200× and 400×
magnification, respectively). Bmi-1 expression mainly localized in nuclei of tumor cells.
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Kaplan-Meier analysis and the log-rank test were used
to evaluate the effect of classic clinicopathological char-
acteristics (including gender, stage, N classification) and
Bmi-1 expression on survival. The expression level of
Bmi-1 protein in esophageal carcinoma was significantly
correlated with patients’ survival time (P = 0.015), that
was the higher level of Bmi-1 expression correlated with
shorter survival time. As shown in Fig. 4, the cumulative
5-year survival rate was 41.3% in the low Bmi-1 expres-
sion group, whereas it was only 33.2% in the high Bmi-1
expression group (P = 0.015, Log-rank).
In addition, N classification, stage and gender were also
significantly correlated with survival in Kaplan-Meier
analysis and log-rank test (for N classification, P < 0.001;
for stage, P = 0.039 and for gender, P = 0.005). But age
was not correlated with survival in Kaplan-Meier analysis
and log-rank test (P > 0.05). We did multivariate survival
analysis, which included Bmi-1 expression level, age,
stage, N classification and gender, to determine if Bmi-1
expression level was an independent prognostic factor of
outcomes. In this analysis, N classification, gender and
Bmi-1 expression were recognized as independent prog-
nostic factors (Table 2). Thus, our findings indicate that
Bmi-1 protein expression level has a significant correla-
tion with prognosis of esophageal carcinoma.
We also analyzed the prognostic value of Bmi-1
expression in selective patient subgroups stratified
according to the stage, T and N classification, respec-
tively. Patients with tumors exhibiting high Bmi-1
expression had significantly shorter overall survival com-
pared with patients with low expression of Bmi-1 in the
T3-T4 subgroup (n = 112; log-rank, P = 0.015; Fig. 5B)
and the N1 subgroup (n = 77; log-rank, P = 0.041; Fig.
5D). A similar analysis of the T1-T2 subgroups (n = 59;
log-rank, P = 0.514; Fig. 5A) and the N0 subgroup (n =
94; log-rank, P =0 . 4 7 5 ;F i g .5 C )d i dn o ts h o ws t a t i s t i -
cally significant differences between patients with differ-
ent Bmi-1 expression level.
Figure 4 Kaplan-Meier curves with univariate analyses (log-
rank) for patients with low Bmi-1 expression versus high Bmi-1
expression tumors. The cumulative 5-y survival rate was 41.3% in
the low Bmi-1 protein expression group (n = 81) (bold line), but it
was only 33.2% in the high expression group (n = 91) (dotted line)
(P < 0.05, Log-rank).
Table 2 Univariate and multivariate analysis of different prognostic parameters in patients with esophageal carcinoma
by Cox-regression analysis
Univariate analysis Multivariate analysis
No. patients p Regression coefficient(SE) p Relative risk 95% confidence interval
Age
<60 103 0.071 0.201(0.196) 0.306 1.222 0.832~1.794
≥60 68
pN metastasis 0.631(0.195) 0.001 1.879 1.283~2.752
Yes 77 <0.001
No 94
Stage -0.347(0.294) 0.237 0.707 0.398~1.257
I-II 99 0.039
III-IV 72
Gender -0.631(0.253) 0.013 0.532 0.324~0.874
Male 129 0.005
Female 42
Bmi-1 expression 0.401(0.195) 0.040 1.501 1.022~2.205
No or low 81 0.015
High 90
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We asked whether overexpression of Bmi-1 could acti-
vate immune system to produce Bmi-1 autoantibodies.
Bmi-1 autoantibodies were determined by ELISA using
purified recombinant Bmi-1 antigen. The mean (SD)
absorbance ratio was 0.128 (0.060) in sera from control
(n = 102) and 0.228 (0.085) in sera from esophageal can-
cer patients (n = 159) (Fig. 6A). Bmi-1 autoantibodies in
sera from ESCC patients was significantly greater than
in healthy controls (P < 0.001). The cutoff for positive
antibody reactivity against Bmi-1 was 0.248, which was
defined as an absorbance greater than 2 SDs above the
mean value of the control. Sera from 62 of 159 esopha-
geal cancer patients (39.0%) were reactive with recombi-
nant Bmi-1 in ELISA, whereas none of the control sera
from healthy volunteers recognized Bmi-1 (Table 3).
The relationship between anti-Bmi-1 autoantibody and
clinicopathological variable si ss h o w ni nT a b l e3 .A n t i -
Bmi-1 antibodies were not statistically associated with T
classification or metastasis. However, correlations were
significant between anti-Bmi-1 and tumor stage (P =
0.040), and lymph node status (N classification; P <
0.001). There was a higher incidence of Bmi-1 antibo-
dies in the advanced disease group than in the early dis-
ease group. Bmi-1 antibodies were also significantly
much prevalent in patients with lymph node metastasis
than those in patients without lymph node metastasis.
Detection of Bmi-1 autoantibodies in sera from patients
with ESCC by Immunoblotting
The 62 sera recognizing Bmi-1 in the ELISA were tested
against recombinant denatured Bmi-1 protein by
Figure 5 Kaplan-Meier analysis of the overall survival of esophageal carcinoma patients categorized according to the T or N
classification and status of Bmi-1 expression. The statistical difference of Bmi-1 high-expressing and low-expressing patients was compared
between T1-T2 (A) and T3-T4 (B) subgroups. The same comparison was carried out in N0 (C) and N1 (D) groups. P values were calculated by
the log-rank test.
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sera (100%) recognized the Mr 41,000 denatured recom-
binant protein Bmi-1 in Western blot analysis. No reac-
tivity was found in any of 20 control sera selected from
healthy volunteers. To illustrate the immunoblot analy-
sis, Fig. 6B shows the staining pattern of representatively
positive sera from esophageal cancer patients and
healthy control. In addition, staining of blotted Bmi-1 by
an anti-Bmi-1 monoclonal antibody and purified recom-
binant Bmi-1 protein were also included.
Discussion
Here, we presented Bmi-1 was upregulated in ESCC and
the expression of Bmi-1 in ESCC was mainly in nuclei
of tumor cells, which was in accordance with the find-
ings in the studies of other cancers [16,24]. We reported
the elevated Bmi-1 expression was correlated with the
stage and pN classification of the disease and poor prog-
nosis of patients. In addition, the presence of Bmi-1
autoantibodies in sera from patients with ESCC may
have clinical utility in esophageal cancer screening,
Figure 6 Detection of Bmi-1 antibody in sera from esophageal cancer patients. (A) Absorbance ratios in anti-Bmi-1 ELISA for sera from
healthy control (Normal) and patients with ESCC (Tumor). The cutoff for positive antibody reactivity against Bmi-1 was 0.248, which was defined
as an absorbance greater than 2 SDs above the mean value of the control. (B) Reactivity of sera from cancer patients with recombinant Bmi-1
protein in Western blotting. Lanes 1-9, stained with 1:100 diluted sera (1 μg Bmi-1/lane). Lanes 1-5, sera from esophageal cancer patients; Lanes
6-9, sera from healthy volunteers; Lane 10. staining of Bmi-1 by anti-Bmi-1 monoclonal antibody (1 μg Bmi-1/lane); Lane 11, staining of purified
recombinant Bmi-1 protein (5 μg Bmi-1/lane)by Coomassie blue staining.
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Taken together, our study suggests that Bmi-1 might
represent a novel indicator for the prognosis of ESCC
patients.
Consistent with our previous studies in other types of
cancer[16,24], we found that Bmi-1 was overexpressed
in immortalized esophageal epithelial cells and ESCC
cell lines as well as in ESCC tissue both at transcrip-
tional and translational level. The accumulation of mul-
tiple genetic alterations may be required over a long
period of time during the development and progression
of ESCC[28]. Cell immortalization is the ability of nor-
mal cells to grow through an indefinite number of divi-
sions in culture[29]. Immortalized cells are capable of
unlimited proliferation and represent the early stage of
transformation before full malignant transformation.
Our results suggest that Bmi-1 may be an early transfor-
mation factor of esophageal epithelial cells. It has been
reported that overexpression of Bmi-1 alone was able to
immortalized human mammary epithelial cells (HMEC)
and nasopharyngeal epithelial cells (NPEC) [16,24].
Thus, it will be important to determine whether overex-
pression of Bmi-1 lead to immortalization of esophageal
epithelial cells.
ESCC shows a poor prognosis because of the occur-
rence of systemic metastasis, mainly via lymphatic ves-
sels[30-32]. Various proteins have been shown to be
associated with development and progression of ESCC,
including cyclin D1[5], Ki-67[6], nm23-H1[7] and Fas
[8]. We have shown that the expression of Bmi-1 is
closely associated with advanced stage and lymph node
metastatic status of esophageal cancer patients, which
is strongly suggesting that Bmi-1 can be used as a
marker to identify subsets of ESCC cancer patients
with more aggressive feature. It suggests that Bmi-1
protein may play a role in tumor metastasis, especially
in lymph node metastasis. As determined in the same
set of samples, our previously study showed that
CENP-H was overexpressed in ESCC[9]. However,
there was no significant correlation between the
expression level of Bmi-1 protein and CENP-H protein
(P = 0.085), though a close examination of co-expres-
sion of the two proteins on survival would be further
analyzed in the future. Importantly, patients with
higher Bmi-1 expression had shorter overall survival
time, whereas patients with lower Bmi-1 expression
had better survival, and Bmi-1 expression was identi-
fied as an independent prognostic factor. These results
are consistent with a recent report about Bmi-1
mRNA expression in ESCC by He, et al [25]. However,
the authors failed to find a clinical relevance with the
expression of Bmi-1 protein. The discrepancy between
our finding and He’s finding may due to the different
antibodies used, or different clinical subjects used in
the two studies. Consistent with other reports, the
anti-Bmi-1 antibody used in our study was tumor cell
nucleus staining, but contrast to He’s report in which
Bmi-1 mainly observed in tumor cell cytoplasm less or
not in nucleus. In addition, we found that in subgroup
of patient with T classification as T3-T4 or N classifi-
cation as N1, higher Bmi-1 expression also indicated a
shorter overall survival time. These results indicate
Bmi-1 is a predictor of lymph node metastasis and
may play a more important role in late stage ESCC.
However, a study in an independent cohort of samples
is required to confirm our findings.
Table 3 Relationships of the presence of anti-Bmi-1 autoantibody with clinicopathologic variables
Anti-Bmi-1
Characteristics Total (n = 159) OD ± SD Negative cases 61.0% Positive cases 39.0% P
Stage 0.040
I 6 0.1883 ± 0.0459 6(100) 0(0.0)
II 72 0.2274 ± 0.0795 46(63.9) 26(36.1)
III 69 0.2394 ± 0.0932 39(56.5) 30(43.5)
IV 12 0.2441 ± 0.0755 5(41.7) 7(58.3)
pT classification 0.747
T1 9 0.1983 ± 0.0552 8(88.9) 1(11.1)
T2 40 0.2312 ± 0.0815 22(55.0) 18(45.0)
T3 80 0.2389 ± 0.0857 49(61.2) 31(38.8)
T4 30 0.2230 ± 0.0927 18(60.0) 12(40.0)
pN classification <0.001
YES 75 0.2596 ± 0.0826 35(46.7) 40(53.3)
NO 84 0.2067 ± 0.0787 62(73.8) 22(26.2)
pMetastasis 0.170
YES 12 0.2441 ± 0.0755 5(41.7) 7(58.3)
NO 147 0.2385 ± 0.0858 91(61.9) 56(38.1)
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1 autoantibodies in sera were a potential new biomarker of
nasopharyngeal carcinoma [17], our results showed that
Bmi-1 autoantibodies were presented in a subgroup of
ESCC sera. Anti-Bmi-1 was significantly correlated with
tumor stage (P = 0.040), and lymph node status (N classifi-
cation; P < 0.001). There was a strong correlation between
Bmi-1 immunostaining and the presence of serum Bmi-1-
Abs (Additional file 3: Table S1). It indicates that Bmi-1
antibodies are more prevalent in sera from patients with
later stage tumor than in sera from patients with early
stage tumor. This may be attributed to higher expression
of Bmi-1 in cancer cells from later stage tumor tissue than
from early stage tumor tissue. There was also higher inci-
dence of Bmi-1 antibodies in sera from patients with
lymph node metastasis than without lymph node metasta-
sis. It is possible that the power of massive lymphocytes
closely contacting with invasive tumor cells, may augment
the immunoreactive to Bmi-1 antigen, which facilitates the
production of Bmi-1 antibodies. Thus, Bmi-1 antibodies
are a novel potential biomarker for ESCC, but it requires
further investigation to determine whether Bmi-1 antibo-
dies could be used as prognostic marker. In ESCC, auto-
immunity has been shown against several proteins,
including cytokeratins[33], p53[34], TRIM21[35], myome-
galin[36], peroxiredoxin VI protein[37] and CDC25b[38].
However, systemic investigations are required before clini-
cal utility of the autoantibodies in diagnosis or prognosis.
Conclusion
This is the first study showing the expression of Bmi-1
in esophageal cancer cell lines as well as tumor tissue,
highlighting the clinical significance of Bmi-1 in esopha-
geal carcinoma. The presence of Bmi-1 autoantibodies
in sera from patients with ESCC may have potential
clinical utility in esophageal cancer diagnosis. Bmi-1
might be used as a valuable prognostic marker for eso-
phageal carcinoma patients. However, further studies
are needed to clarify the mechanism by which Bmi-1 is
involved in the development and progression of esopha-
geal carcinoma and its exact role in the regulation of
carcinogenesis in esophageal carcinoma.
Additional material
Additional file 1: Expression of Bmi-1 in primary normal esophageal
epithelial cells (NEECs) and esophageal carcinoma cell lines by
Western blot analysis. The expression of Bmi-1 protein in ESCC cell
lines (108CA, Kyse 140, Eca-109) and the primary cultured normal
esophageal epithelial cells from two independent donors analyzed by
Western blot was shown in this figure. A. Primary culture of NEEC (the
arrow shows a piece of biopsy). B. Western blot analysis of E-cadherin in
NEEC1, NEEC2. a-Tubulin was used as a loading control. C. Western blot
analysis of Bmi-1 in NEEC1, NEEC2 and various esophageal carcinoma cell
lines. a-Tubulin was used as a loading control.
Additional file 2: Expression of Bmi-1 in the 8 paired fresh tissue
samples by immunohistochemical analysis. Representative
immunohistochemistry staining for Bmi-1 protein in the 8 pairs of ESCC
specimens used in western blot assay was shown in this figure (Original
magnification, 200×).
Additional file 3: The correlation between Bmi-1 immunostaining
and the presence of serum Bmi-1-Abs. The correlation between Bmi-1
immunostaining in 40 tumor samples and the presence of serum Bmi-1-
Abs in those matched serum samples was shown in this table.
Acknowledgements
This research was supported in part by grants from the Ministry of Science
and Technology of China (No.2007AA02Z477, 2006AA02Z4B4 and
2006AA02A403), National Natural Science Foundation of China (No.
30570701 and 30630068), the Ph.D. Programs Foundation of Ministry of
Education of China (No. 20070558270), and the Natural Science Foundation
of Guangdong Province, China (No.04300288).
Author details
1Department of Experimental Research, Sun Yat-sen University cancer center,
Guangzhou, China.
2State Key Laboratory of Oncology in South China,
Guangzhou, China.
3Department of Medical Oncology, The Central Hospital
of Xuhui District, Shanghai, China.
4Department of Thoracic Surgery, Sun Yat-
sen University cancer center, Guangzhou, China.
5School of Pharmaceutical
Sciences, Sun Yat-sen University, Guangzhou, China.
Authors’ contributions
XZG and WLL were responsible for data collection and analysis, experiment
job, interpretation of the results, and writing the manuscript. LJZ, GZ, LBS,
LHX were responsible for conducting the data analysis in cooperation with
JYW, SG and YMC. QLK, MZL were responsible for reviewing and scoring the
degree of immunostaining of sections. MSZ was responsible for
experimental design, analysis and interpretation. All authors have read and
approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 9 September 2009 Accepted: 1 September 2010
Published: 1 September 2010
References
1. Enzinger PC, Mayer RJ: Esophageal cancer. The New England journal of
medicine 2003, 349(23):2241-2252.
2. Lam KY, Ma L: Pathology of esophageal cancers: local experience and
current insights. Chinese medical journal 1997, 110(6):459-464.
3. Zhang H, Jin Y, Chen X, Jin C, Law S, Tsao SW, Kwong YL: Cytogenetic
aberrations in immortalization of esophageal epithelial cells. Cancer
genetics and cytogenetics 2006, 165(1):25-35.
4. Cervantes J: Update on the pathogenesis and immunotherapy of
esophageal squamous cell carcinoma. Rev Gastroenterol Peru 2004,
24(2):165-170.
5. Naitoh H, Shibata J, Kawaguchi A, Kodama M, Hattori T: Overexpression
and localization of cyclin D1 mRNA and antigen in esophageal cancer.
The American journal of pathology 1995, 146(5):1161-1169.
6. Kakegawa T, Yamana H: Postoperative prognostic factors for carcinoma of
the thoracic esophagus. Gan to kagaku ryoho 1995, 22(4):573-579.
7. Iizuka N, Tangoku A, Hayashi H, Yosino S, Abe T, Morioka T, Oka M: The
association between nm23-H1 expression and survival in patients with
esophageal squamous cell carcinoma. Cancer letters 1999, 138(1-
2):139-144.
8. Chan KW, Lee PY, Lam AK, Law S, Wong J, Srivastava G: Clinical relevance
of Fas expression in oesophageal squamous cell carcinoma. Journal of
clinical pathology 2006, 59(1):101-104.
9. Guo XZ, Zhang G, Wang JY, Liu WL, Wang F, Dong JQ, Xu LH, Cao JY,
Song LB, Zeng MS: Prognostic relevance of Centromere protein H
expression in esophageal carcinoma. BMC cancer 2008, 8:233.
Liu et al. BMC Cancer 2010, 10:467
http://www.biomedcentral.com/1471-2407/10/467
Page 11 of 1210. Haupt Y, Alexander WS, Barri G, Klinken SP, Adams JM: Novel zinc finger
gene implicated as myc collaborator by retrovirally accelerated
lymphomagenesis in E mu-myc transgenic mice. Cell 1991, 65(5):753-763.
11. van Lohuizen M, Verbeek S, Scheijen B, Wientjens E, van der Gulden H,
Berns A: Identification of cooperating oncogenes in E mu-myc transgenic
mice by provirus tagging. Cell 1991, 65(5):737-752.
12. van der Lugt NM, Domen J, Linders K, van Roon M, Robanus-Maandag E, te
Riele H, van der Valk M, Deschamps J, Sofroniew M, van Lohuizen M, et al:
Posterior transformation, neurological abnormalities, and severe
hematopoietic defects in mice with a targeted deletion of the bmi-1
proto-oncogene. Genes & development 1994, 8(7):757-769.
13. Pirrotta V: Polycombing the genome: PcG, trxG, and chromatin silencing.
Cell 1998, 93(3):333-336.
14. Jacobs JJ, Kieboom K, Marino S, DePinho RA, van Lohuizen M: The
oncogene and Polycomb-group gene bmi-1 regulates cell proliferation
and senescence through the ink4a locus. Nature 1999, 397(6715):164-168.
15. Dimri GP, Martinez JL, Jacobs JJ, Keblusek P, Itahana K, Van Lohuizen M,
Campisi J, Wazer DE, Band V: The Bmi-1 oncogene induces telomerase
activity and immortalizes human mammary epithelial cells. Cancer
research 2002, 62(16):4736-4745.
16. Song LB, Zeng MS, Liao WT, Zhang L, Mo HY, Liu WL, Shao JY, Wu QL,
Li MZ, Xia YF, et al: Bmi-1 is a novel molecular marker of nasopharyngeal
carcinoma progression and immortalizes primary human
nasopharyngeal epithelial cells. Cancer Res 2006, 66(12):6225-6232.
17. Tong YQ, Liu B, Huang J, Liu Y, Guo FJ, Zhou GH, Xie PL, Li YH, Hu JY,
Li GC: BMI-1 autoantibody in serum as a new potential biomarker of
nasopharyngeal carcinoma. Cancer biology & therapy 2008, 7(3):340-344.
18. Bea S, Tort F, Pinyol M, Puig X, Hernandez L, Hernandez S, Fernandez PL,
van Lohuizen M, Colomer D, Campo E: BMI-1 gene amplification and
overexpression in hematological malignancies occur mainly in mantle
cell lymphomas. Cancer research 2001, 61(6):2409-2412.
19. Vonlanthen S, Heighway J, Altermatt HJ, Gugger M, Kappeler A, Borner MM,
van Lohuizen M, Betticher DC: The bmi-1 oncoprotein is differentially
expressed in non-small cell lung cancer and correlates with INK4A-ARF
locus expression. British journal of cancer 2001, 84(10):1372-1376.
20. van Kemenade FJ, Raaphorst FM, Blokzijl T, Fieret E, Hamer KM, Satijn DP,
Otte AP, Meijer CJ: Coexpression of BMI-1 and EZH2 polycomb-group
proteins is associated with cycling cells and degree of malignancy in B-
cell non-Hodgkin lymphoma. Blood 2001, 97(12):3896-3901.
21. Kim JH, Yoon SY, Jeong SH, Kim SY, Moon SK, Joo JH, Lee Y, Choe IS,
Kim JW: Overexpression of Bmi-1 oncoprotein correlates with axillary
lymph node metastases in invasive ductal breast cancer. Breast
(Edinburgh, Scotland) 2004, 13(5):383-388.
22. Kim JH, Yoon SY, Kim CN, Joo JH, Moon SK, Choe IS, Choe YK, Kim JW: The
Bmi-1 oncoprotein is overexpressed in human colorectal cancer and
correlates with the reduced p16INK4a/p14ARF proteins. Cancer letters
2004, 203(2):217-224.
23. Glinsky GV, Berezovska O, Glinskii AB: Microarray analysis identifies a
death-from-cancer signature predicting therapy failure in patients with
multiple types of cancer. The Journal of clinical investigation 2005,
115(6):1503-1521.
24. Liu JH, Song LB, Zhang X, Guo BH, Feng Y, Li XX, Liao WT, Zeng MS,
Huang KH: Bmi-1 expression predicts prognosis for patients with gastric
carcinoma. Journal of surgical oncology 2008, 97(3):267-272.
25. He XT, Cao XF, Ji L, Zhu B, Lv J, Wang DD, Lu PH, Cui HG: Association
between Bmi1 and clinicopathological status of esophageal squamous
cell carcinoma. World J Gastroenterol 2009, 15(19):2389-2394.
26. Sobin LH, Fleming ID: TNM Classification of Malignant Tumors, fifth
edition (1997). Union Internationale Contre le Cancer and the American
Joint Committee on Cancer. Cancer 1997, 80(9):1803-1804.
27. Ciocca DR, Clark GM, Tandon AK, Fuqua SA, Welch WJ, McGuire WL: Heat
shock protein hsp70 in patients with axillary lymph node-negative
breast cancer: prognostic implications. Journal of the National Cancer
Institute 1993, 85(7):570-574.
28. Mandard AM, Hainaut P, Hollstein M: Genetic steps in the development of
squamous cell carcinoma of the esophagus. Mutation research 2000,
462(2-3):335-342.
29. Shay JW, Wright WE: Senescence and immortalization: role of telomeres
and telomerase. Carcinogenesis 2005, 26(5):867-874.
30. Dawsey SM, Wang GQ, Weinstein WM, Lewin KJ, Liu FS, Wiggett S,
Nieberg RK, Li JY, Taylor PR: Squamous dysplasia and early esophageal
cancer in the Linxian region of China: distinctive endoscopic lesions.
Gastroenterology 1993, 105(5):1333-1340.
31. Shiozaki H, Doki Y, Kawanishi K, Shamma A, Yano M, Inoue M, Monden M:
Clinical application of malignancy potential grading as a prognostic
factor of human esophageal cancers. Surgery 2000, 127(5):552-561.
32. Eloubeidi MA, Desmond R, Arguedas MR, Reed CE, Wilcox CM: Prognostic
factors for the survival of patients with esophageal carcinoma in the U.
S.: the importance of tumor length and lymph node status. Cancer 2002,
95(7):1434-1443.
33. Veale RB, Thornley AL, Scott E, Antoni A, Segal I: Quantitation of
autoantibodies to cytokeratins in sera from patients with squamous cell
carcinoma of the oesophagus. Br J Cancer 1988, 58(6):767-772.
34. Bergqvist AS, Bergqvist M, Brattstrom D, Hesselius P, Larsson A, Brodin O,
Wagenius G: Serum p53 autoantibodies as prognostic marker in patients
with oesophageal carcinoma. Anticancer Res 2001, 21(6A):4141-4145.
35. Kuboshima M, Shimada H, Liu TL, Nomura F, Takiguchi M, Hiwasa T,
Ochiai T: Presence of serum tripartite motif-containing 21 antibodies in
patients with esophageal squamous cell carcinoma. Cancer Sci 2006,
97(5):380-386.
36. Shimada H, Kuboshima M, Shiratori T, Nabeya Y, Takeuchi A, Takagi H,
Nomura F, Takiguchi M, Ochiai T, Hiwasa T: Serum anti-myomegalin
antibodies in patients with esophageal squamous cell carcinoma. Int J
Oncol 2007, 30(1):97-103.
37. Fujita Y, Nakanishi T, Hiramatsu M, Mabuchi H, Miyamoto Y, Miyamoto A,
Shimizu A, Tanigawa N: Proteomics-based approach identifying
autoantibody against peroxiredoxin VI as a novel serum marker in
esophageal squamous cell carcinoma. Clin Cancer Res 2006,
12(21):6415-6420.
38. Liu WL, Zhang G, Wang JY, Cao JY, Guo XZ, Xu LH, Li MZ, Song LB,
Huang WL, Zeng MS: Proteomics-based identification of autoantibody
against CDC25B as a novel serum marker in esophageal squamous cell
carcinoma. Biochem Biophys Res Commun 2008, 375(3):440-445.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2407/10/467/prepub
doi:10.1186/1471-2407-10-467
Cite this article as: Liu et al.: Prognostic relevance of Bmi-1 expression
and autoantibodies in esophageal squamous cell carcinoma. BMC
Cancer 2010 10:467.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Liu et al. BMC Cancer 2010, 10:467
http://www.biomedcentral.com/1471-2407/10/467
Page 12 of 12